Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Sellas Life Sciences Group, Inc. SLS

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-26.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2022 · Revenue 1.0 · Net income -41.3
4M8M-30M-60M
201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -4195.0% · Net ·
-2000%-4000%
201020172025
ROE
FY2025 · ROE -66.9%
-200%-400%-600%
201020172025
Three returns, three denominators.

Each USD of equity lost 67 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2016 · FCF -11.9
-20M-40M
201020172025
Net buybacks $M Dividends $M
FY2019 · Dividends 0.0 · Net buybacks ·
-5M-10M
2010201720182019

Total assetsUSD 78.3M
EquityUSD 70.9M
CashUSD 71.8M
Current ratio10.72×

Equity funds 90% of total assets.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SLS, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B◌◌◌0.00.00.0◌◌◌◌◌0.00.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
EBITDA $B◌◌◌◌◌◌◌◌◌−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B0.00.00.00.0−0.0−0.0−0.0−0.00.00.00.00.00.0−0.0◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.1−0.0−0.0−0.0
Free cash flow $B◌◌◌◌◌◌◌◌◌−0.0−0.0−0.0−0.0◌−0.0−0.0
EPS, diluted $−0.25−0.50−1.34−2.13−1.34−2.11−10.92−157.72−10.44−18.66−8.23−6.13−0.85−0.56−0.32−0.67
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %——————−0−2−0———————
ROE %−66.9——−327.8−85.7−98.4−340.3−756.5———−170.5−455.8−184.7−183.1−493.5
Shares out B0.150.070.030.020.020.010.010.020.010.020.160.110.110.080.050.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image